Loading...
•
Dec 31, 2022
Boston Scientific Q4 2022 Earnings Report
Boston Scientific reported Q4 2022 earnings, with net sales increasing by 3.7% and adjusted EPS meeting guidance.
Key Takeaways
Boston Scientific's Q4 2022 results showed a 3.7% increase in net sales to $3.242 billion. The company's GAAP EPS was $0.09, while adjusted EPS was $0.45, which included a negative impact of approximately $0.04 due to Italian payback provisions. For the full year, net sales grew by 6.7% to $12.682 billion, with GAAP EPS at $0.45 and adjusted EPS at $1.71.
Net sales for Q4 2022 reached $3.242 billion, a 3.7% increase on a reported basis.
GAAP net income available to common stockholders was $0.09 per share, while adjusted EPS was $0.45.
MedSurg segment net sales increased by 4.4% reported and 8.5% organic.
Cardiovascular segment net sales increased by 6.4% reported and 9.4% organic.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope, Middle East & Africa Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
The company estimates net sales growth for the full year 2023 to be in the range of approximately 5 to 7 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $1.11 to $1.21 and estimates adjusted EPS, excluding certain charges (credits) of $1.86 to $1.93.
Positive Outlook
- Full year 2023 reported net sales growth is expected to be between 5% and 7%.
- Full year 2023 organic net sales growth is projected to be between 6% and 8%.
- Full year 2023 GAAP EPS is estimated to be between $1.11 and $1.21.
- Full year 2023 adjusted EPS is projected to be between $1.86 and $1.93.
- First quarter 2023 reported net sales growth is expected to be in the range of approximately 3 to 5 percent.
Challenges Ahead
- Foreign currency fluctuations are expected to negatively impact net sales growth.
- Certain acquisitions and divestitures may impact net sales growth.
- Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
- First quarter organic guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
- The company estimates EPS on a GAAP basis in a range of $0.23 to $0.26 for Q1 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income